Early haematologic response to anifrolumab in systemic lupus erythematosus: results from the european multicentre EFFORT-SLE study
Clicks: 2
ID: 324639
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #155 of 202 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 202 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVES: To evaluate the efficacy and safety of anifrolumab (ANI) for the hematologic manifestations of systemic lupus erythematosus (SLE) in routine clinical practice. METHODS: In this retrospective multicentre European study, adult patients with SLE presenting ≥1 disease-related hematologic abnormality at ANI initiation were included. Clinical and laboratory data were collected at baseline and at 3, 6, 12, 18 and 24 months. Complete hematologic response (CHR) was defined as normalisation of all baseline abnormalities, whereas partial hematologic response (PHR) as normalisation of at least one affected lineage. RESULTS: Forty-seven patients from seven European countries were included (91.5% female). ANI was specifically initiated for hematologic involvement in 21/47 (44.7%), whereas 26/47 (55.3%) started treatment for other SLE manifestations but had ≥1 hematologic abnormality at baseline. CHR was achieved in 8/43 (18.6%) patients at 3 months and cumulatively in 14/46 (30.4%) within 6 months (overall 17/47, 36.2%), with comparable rates regardless of treatment indication. PHR occurred in 17/43 (39.5%) at 3 months and 11/37 (29.7%) at 6 months. Haemoglobin, leukocyte and lymphocyte counts significantly improved by month 3, whereas platelet counts showed a non-significant increase. Higher baseline CRP, ESR and SLE-DAS were associated with lack of CHR. Twelve patients (25.5%) discontinued ANI and 17 (36.2%) experienced adverse events without discontinuation. CONCLUSION: ANI was associated with early hematologic improvement, with one-third of patients achieving complete normalization under a stringent definition of remission. Responses involved multiple hematologic lineages and were less frequent in patients with higher inflammatory activity, although confirmation in broader populations is warranted.
| Reference Key |
openalex_W7202199425
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Michela Gasparotto, Alessandra Bettiol, Ginevra De Marchi, Edoardo Biancalana, Giulia Duro, Filippo Fagni, Alice Horisberger, Joško Mitrović, Alessia Nano, Katarzyna Wawrzycka‐Adamczyk, Myriam Reisch, Lea Šalamon, Georg Schett, Ladislav Šenolt, Elena Silvestri, Jens Thiel, Paola Tomietto, Krzysztof Wójcik, Jakub Závada, Luca Quartuccio, Giacomo Emmi |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag400
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.